Investigational drug · Phase 3
DTG
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Infection, Human Immunodeficiency Virus, HIV Infections.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
352
Any phase or sponsor naming "DTG"
First trial start
2016
Oct 27, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DTG", any sponsor or status.
Conditions studied
As listed on its trial records.
- Infection, Human Immunodeficiency Virus
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "DTG" as an intervention, largest first.
- Investigating the Optimal Management of Dolutegravir ResistanceActive, not recruiting
University of NairobiAcademic, hospital or other
NCT06762054 · 6,624 participants · Start Mar 3, 2025 · Primary completion Feb 15, 2027
Drug: Continue DTG-based antiretroviral therapy · For: HIV-1-infection
Sites: Kisumu, Kenya; Mombasa, Kenya; Nairobi, Kenya · 9 sites in all
- HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in BrazilActive, not recruiting
Federal University of São PauloAcademic, hospital or other
NCT04453436 · 2,500 participants (planned) · Start Sep 1, 2023 · Primary completion Dec 31, 2024
Drug: Tenofovir Disoproxil · For: HIV; Drug; Resistance
Sites: São Paulo, Brazil
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTPivotal-lookingRecruiting
Africa Health Research InstituteAcademic, hospital or other
NCT06250504 · 2,052 participants (planned) · Start Feb 27, 2024 · Primary completion Apr 30, 2026
Drug: APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring and 2 more · For: HIV Infections
Sites: Somkele, South Africa
- Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING StudyActive, not recruiting
Erasmus Medical CenterAcademic, hospital or other
NCT04707326 · 2,040 participants · Start Nov 1, 2019 · Primary completion Nov 1, 2023
Drug: Dolutegravir / Lamivudine Pill · For: Hiv
Sites: Arnhem, Netherlands; Eindhoven, Netherlands; Enschede, Netherlands · 9 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00042289 · 1,578 participants · Start Jun 9, 2003 · Primary completion Sep 30, 2020
Drug: atazanavir/cobicistat; darunavir/ritonavir dosage #1 and 55 more · For: HIV Infections
Sites: Birmingham, Alabama; La Jolla, California; Long Beach, California · 62 sites in all
- Dolutegravir in Real Life in LesothoCompleted
Swiss Tropical & Public Health InstituteAcademic, hospital or other
NCT04238767 · 1,433 participants · Start Feb 10, 2020 · Primary completion May 19, 2021
Drug: Dolutegravir · For: HIV-1-infection
Sites: Butha-Buthe, Lesotho · 2 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02140255 · 1,120 participants (planned) · Start Jan 23, 2015 · Primary completion Jan 31, 2028
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP) and 5 more · For: HIV Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 47 sites in all
- ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyPivotal-lookingCompleted
Professor Francois VenterAcademic, hospital or other
NCT03122262 · 1,110 participants · Start Jan 16, 2017 · Primary completion Apr 30, 2022
Drug: Dolutegravir; Tenofovir Alafenamide and 2 more · For: HIV-1 Infection
Sites: Johannesburg, South Africa · 4 sites in all
- POC HIV Testing and Early DTG Use for InfantsActive, not recruiting
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT05393193 · 900 participants (planned) · Start Jul 4, 2022 · Primary completion Mar 16, 2026
Drug: DTG/ABC/3TC · For: HIV
Sites: Gaborone, Botswana
- Antiretroviral Therapy for Acute and Chronic HIV InfectionPivotal-lookingRecruiting
SEARCH Research FoundationAcademic, hospital or other
NCT00796263 · 900 participants (planned) · Start May 13, 2009 · Primary completion Jun 2033
Drug: HAART · For: Acute HIV Infection; Chronic HIV Infection
Sites: Bangkok, Thailand
Newest research
PubMed records naming it or its code names, newest first.
- A multi-dimensional attention-based framework for personalized driver fatigue assessment for proactive commercial-vehicle crash prevention.
Yang J, Lee JJ, Antoniou C · Accid Anal Prev 2027
- Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience.
Ankunda C, Emunyu J, Namasambi S, et al. · HIV Res Clin Pract 2026
- Integrated multispectroscopic and DFT analysis of molecular heterogeneity in Garabagh asphaltenes (Azerbaijan).
Yolchuyeva UJ, Abbasov VM, Abbasov OR, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2026
- Prevalence and associated factors of overweight/obesity and central obesity among adults receiving dolutegravir-based first-line treatment in health facilities at hawassa city administration, sidama region.
Hirigo AT, Ketema W, Debebe Z, et al. · Obes Pillars 2026
- Promoting the production of 5-hydroxymethylfurfural from glucose via a deep eutectic solvent-dimethyl sulfoxide binary system coupled with AlCl3·6H2O.
Liu D, Qian J, Chen X, et al. · Carbohydr Res 2026
- Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.
Parczewski M, Zazzi M, Mielczak K, et al. · AIDS 2026
Also in development for Infection, Human Immunodeficiency Virus
- ACC017Phase 33 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- FTCPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.